Amgen Launches Rituxan Rival In US
As Company Reflects On Future Of Biosimilars In US
Executive Summary
Amgen has announced the launch of its biosimilar version of Rituxan (rituximab), Riabni, in the US market, further expanding the firm’s oncology biosimilars portfolio.
You may also be interested in...
Amgen Rivals Teva With Rituximab Approved For RA
Amgen has added a further treatment for inflammatory diseases to its vast portfolio, with the FDA approving its rituximab biosimilar Riabni for rheumatoid arthritis.
Teva: Amgen’s Interchangeable Humira Biosimilar Too Late For January 2023
Teva discussed its proposed rivals in the US biosimilar adalimumab space, biosimilar business development plans and prioritizing debt during its Q3 earnings call. The Israeli firm’s revenues succumbed to challenges in the US generics space.
Amgen Optimistic Over Inflammation Biosimilars Ahead Of Ustekinumab
Amgen has once again touched on its impending expansion into US inflammation/immunology biosimilars, with launches for adalimumab and ustekinumab scheduled for the coming years.